⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NNVC News
NanoViricides Inc.
Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides
accessnewswire.com
NNVC
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
accessnewswire.com
NNVC
Form 8-K
sec.gov
SCTH
NNVC
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides
accessnewswire.com
NNVC
GILD
SIGA
EBS
NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete
accessnewswire.com
NNVC
MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
accessnewswire.com
NNVC
Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
accessnewswire.com
NNVC
NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres
accessnewswire.com
NNVC
GILD
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
accessnewswire.com
COE
ACCS
ASNS
DRTS
AREB
BKYI
FUFU
CJMB
DVLT
FBLG
MEHA
HCTI
INDO
JUNS
KAPA
LIXT
MYSZ
NNVC
HOVR
NOMA
OPTT
OWLS
PERF
PHIO
PROP
PRPO
SJ
LITM
SOPA
SNGX
XHLD
TYGO
TIVC
TRX
WGRX
WWR
ZENA
FLGC
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
accessnewswire.com
COE
ACCS
ASNS
DRTS
AREB
BKYI
FUFU
CJMB
DVLT
FBLG
MEHA
HCTI
INDO
JUNS
KAPA
LIXT
MYSZ
NNVC
HOVR
NOMA
OPTT
OWLS
PERF
PHIO
PROP
PRPO
SJ
LITM
SOPA
SNGX
XHLD
TYGO
TIVC
TRX
WGRX
WWR
ZENA
FLGC